JP2022530095A5 - - Google Patents
Info
- Publication number
- JP2022530095A5 JP2022530095A5 JP2021563234A JP2021563234A JP2022530095A5 JP 2022530095 A5 JP2022530095 A5 JP 2022530095A5 JP 2021563234 A JP2021563234 A JP 2021563234A JP 2021563234 A JP2021563234 A JP 2021563234A JP 2022530095 A5 JP2022530095 A5 JP 2022530095A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837947P | 2019-04-24 | 2019-04-24 | |
| US62/837,947 | 2019-04-24 | ||
| PCT/US2020/029642 WO2020219766A1 (en) | 2019-04-24 | 2020-04-23 | Compositions useful in treatment of rett syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530095A JP2022530095A (ja) | 2022-06-27 |
| JPWO2020219766A5 JPWO2020219766A5 (https=) | 2023-04-28 |
| JP2022530095A5 true JP2022530095A5 (https=) | 2023-04-28 |
Family
ID=72941315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563234A Pending JP2022530095A (ja) | 2019-04-24 | 2020-04-23 | レット症候群の治療に有用な組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220202960A1 (https=) |
| EP (1) | EP3973060A4 (https=) |
| JP (1) | JP2022530095A (https=) |
| KR (1) | KR20220003553A (https=) |
| CN (1) | CN114026236A (https=) |
| AU (1) | AU2020261051A1 (https=) |
| CA (1) | CA3133889A1 (https=) |
| SG (1) | SG11202111279QA (https=) |
| WO (1) | WO2020219766A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230304034A1 (en) * | 2020-05-12 | 2023-09-28 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| WO2022094078A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| AU2022369293A1 (en) * | 2021-10-18 | 2024-05-16 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| US20250312486A1 (en) * | 2022-04-18 | 2025-10-09 | City Of Hope | Compositions for restoring mecp2 gene function and methods of use thereof |
| WO2024081551A1 (en) * | 2022-10-10 | 2024-04-18 | Passage Bio, Inc. | Method of purifying full recombinant aav particles |
| EP4715058A1 (en) * | 2023-05-15 | 2026-03-25 | Genecombio Ltd. | Gene therapy for rett syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069584A2 (en) * | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| PL2002003T3 (pl) * | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Wektor genetyczny zawierający mi-RNA |
| PL2010563T3 (pl) * | 2006-04-07 | 2011-11-30 | Georg August Univ Goettingen Stiftung Oeffentlichen Rechts | Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| EP3452101A2 (en) * | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| CA3052487A1 (en) * | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
| JP7455579B2 (ja) * | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途 |
| JP2020513831A (ja) * | 2017-03-24 | 2020-05-21 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ エジンバラ | ＭｅＣＰ２発現カセット |
| US11680275B2 (en) * | 2017-06-06 | 2023-06-20 | University Of Massachusetts | Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome |
-
2020
- 2020-04-23 CA CA3133889A patent/CA3133889A1/en active Pending
- 2020-04-23 AU AU2020261051A patent/AU2020261051A1/en not_active Abandoned
- 2020-04-23 US US17/605,827 patent/US20220202960A1/en not_active Abandoned
- 2020-04-23 KR KR1020217037510A patent/KR20220003553A/ko active Pending
- 2020-04-23 SG SG11202111279QA patent/SG11202111279QA/en unknown
- 2020-04-23 CN CN202080046692.7A patent/CN114026236A/zh active Pending
- 2020-04-23 JP JP2021563234A patent/JP2022530095A/ja active Pending
- 2020-04-23 WO PCT/US2020/029642 patent/WO2020219766A1/en not_active Ceased
- 2020-04-23 EP EP20795847.1A patent/EP3973060A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530095A5 (https=) | ||
| CL2025004153A1 (es) | Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso. | |
| CN305651099S (https=) | ||
| CN305644862S (https=) | ||
| CN305529969S (https=) | ||
| CN305528563S (https=) | ||
| CN305528520S (https=) | ||
| CN305527265S (https=) | ||
| CN305877144S (https=) | ||
| CN305875660S (https=) | ||
| CN305873204S (https=) | ||
| CN305871212S (https=) | ||
| CN305865987S (https=) | ||
| CN305864055S (https=) | ||
| CN305863707S (https=) | ||
| CN305647927S (https=) | ||
| CN305860348S (https=) | ||
| CN305859234S (https=) | ||
| CN305845318S (https=) | ||
| CN305842319S (https=) | ||
| CN305841060S (https=) | ||
| CN305810085S (https=) | ||
| CN305790923S (https=) | ||
| CN305725722S (https=) | ||
| CN305696580S (https=) |